Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real World Evidence Study on Metastatic Prostate Cancer Patient Characteristics, Treatment Patterns and Outcomes in the Pirkanmaa Hospital District in Finland

NCT05701007 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05701007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05701007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real World Evidence Study on Metastatic Prostate Cancer Patient Characteristics, Treatment Patterns and Outcomes in the Pirkanmaa Hospital District in Finland
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
February 13, 2023
Completion date
April 10, 2024
Enrollment
1,083 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration resistant prostate cancer (mcrpc), metastatic castration sensitive prostate cancer (mcspc)